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Cardiovascular disease (CVD) is the leading cause of mortality in patients with type 1
diabetes (T1D). The cardiovascular autonomic neuropathy (CAN), although considered
as an independent risk factor for CVD, remains underdiagnosed. The aim of this paper
was to determine the prevalence, predictors of CAN in patients with T1D and its asso-
ciation with other chronic complications of diabetes. Patients with T1D underwent a
clinical-epidemiological survey, had blood and urinary samples collected, performed oph-
thalmoscopic and clinical neurological examination and cardiovascular reflex tests. One
hundred and fifty one patients with T1D, 53.6% female, 45.7% Caucasian, mean age
of 33.4±13 years, diabetes duration of 16.3±9.5 years, and glycated hemoglobin lev-
els of 9.1±2% were evaluated. The prevalence of CAN in the studied population was
30.5%. CAN was associated with age (p=0.01), diabetes duration (p=0.036), hyperten-
sion (p=0.001), resting heart rate (HR) (p=0.000), HbA1c (p=0.048), urea (p=0.000),
creatinine (p=0.008), glomerular filtration rate (p=0.000), urinary albumin concentration
(p=0.000), LDL (p=0.048), free T4 (p=0.023), hemoglobin (p=0.01) and presence of
retinopathy (p=0.000), nephropathy (p=0.000) and diabetic neuropathy (p=0.000), the
following symptoms syncope (p=0.000), post prandial nausea (p=0.042), early satiety
(p=0.031), sexual dysfunction (p=0.049), and gustatory sweating (p= 0.018). In logistic
regression model, it was observed that only resting HR, diabetic neuropathy, and retinopa-
thy were independent associated with CAN. In conclusion, CAN is a common chronic
complication of T1D affecting about 30% of the studied population and is associated with
the presence of other chronic complications. Indicators of CAN included age, diabetes
duration, hypertension, resting HR, diabetic neuropathy and retinopathy, and symptoms
suggestive of autonomic neuropathy. This study confirms the importance of systematic
and early screening for CAN.
Keywords: type 1 diabetes, cardiovascular risk, cardiovascular autonomic neuropathy, heart rate variability, chronic
complications
INTRODUCTION
Type 1 diabetes (T1D) is the most common endocrine disorder
of childhood and adolescence affecting about 10–20 million peo-
ple worldwide (1). Poor glycemic control is associated with the
development of micro and macrovascular chronic complications
leading to a major impact on morbidity and mortality (2). Cardio-
vascular disease (CVD) is the leading cause of mortality in patients
with T1D (3–5).
Cardiovascular autonomic neuropathy (CAN) although con-
sidered a common diabetic chronic complication (6) and asso-
ciated with increased cardiovascular morbidity and mortality,
remains underdiagnosed (6, 7).
Depending on the methodology and diagnostic criteria, the
prevalence of CAN ranges from 2.6 to 90% among patients with
diabetes and its prevalence increases with age, diabetes dura-
tion, and inappropriate glycemic control (8, 9) and may be
associated with peripheral neuropathy (up to 62.5% of cases)
and the presence of other cardiovascular risk factors, such as
hypertension, dyslipidemia, diabetic nephropathy and retinopa-
thy, arterial stiffness, left ventricular hypertrophy, and diastolic
dysfunction (9, 10).
Cardiovascular autonomic neuropathy has been identified as
a strong predictor of CVD in both patients with T1D and
type 2 diabetes (T2D). Patients with diabetes and CAN have 5-
year mortality rates ranging from 16 to 53%, depending on its
severity (8).
In the DIAD study (Detection of silent myocardial ischemia in
asymptomatic diabetic subjects) conducted in patients with T2D,
the presence of CAN, determined by abnormal Valsalva ratio,
was a strong predictor of silent myocardial ischemia, regardless
of the presence of traditional cardiovascular risk factors such as
hypertension, age, sex, and smoking (11–13).
Data from the Action to Control Cardiovascular Risk in Dia-
betes (ACCORD) study showed that patients with CAN presented
mortality rate approximately 1.55–2.14 times higher than patients
without CAN (14).
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Unfortunately, clinical symptoms of CAN appears late in the
course of the disease, which makes the use of cardiovascular reflex
tests critical for CAN diagnosis (15–17). However, the presence
of symptoms suggestive of dysautonomia as syncope, postpran-
dial hypotension, exercise intolerance, resting tachycardia, gastro-
paresis, diarrhea, urinary incontinence, and erectile dysfunction
may suggest the presence of CAN and these patients should be
investigated (7).
According to Toronto Consensus, the analysis of heart rate
variability (HRV) using the variation of RR intervals of the electro-
cardiogram are sensitive and specific methods used for the early
detection of CAN and seven parameters can be used to assess
the presence of CAN: the three spectral analysis frequency bands
[very low frequency (VLF), low frequency (LF) and high frequency
(HF)] and four tests proposed by Ewing [heart rate (HR) response
to the Valsalva maneuver, to deep breathing, and to standing and
the blood pressure response to standing] (17, 18).
The consensus of Diabetic Neuropathy Conference held in San
Antonio in 1992 (15), of the Toronto Diabetic Neuropathy (17, 18),
and the Study Group on the Diabetic Neuropathy Italian Society of
Diabetology (16), advocates the use of cardiovascular reflex tests
(deep breathing test, orthostatic test, OH test, and Valsalva test) as
the gold standard tests for the diagnosis of CAN.
The time and frequency-domain HRV parameters seem to be
more sensitive and changes in HRV may occur earlier than alter-
ations on cardiovascular reflex tests. Tannus et al. (19) showed that
short-term spectral analysis of HRV (VLF, HF, and LF) despite
being a low cost, non-invasive, easy to perform, and does not
require active cooperation of patients, demonstrated poor repro-
ducibility (20–24) being thus considered as additional tests for the
diagnosis of NAC (15–17).
Considering the paucity of data in the literature on the preva-
lence of CAN in the Brazilian population with T1D, this study
aimed to determine the prevalence of CAN in Brazilian patients
with T1D and to identify clinical and laboratory factors associated
with the presence of CAN.
MATERIALS AND METHODS
This study is a cross-sectional study conducted in patients with
T1D attended in the diabetes unit of State University of Rio de
Janeiro. Written informed consent for the study was obtained from
all of the patients aged 18 years or older or from the parents or
guardians of the patients younger than 18 years. The study was
approved by each local center’s ethics committee.
The inclusion criteria were patients with T1D, defined by a
physician based on the criteria of American Diabetes Association
(ADA) and Brazilian Diabetes Society (BDS), which include age
less than 40 years old at diagnosis, typical clinical presentation
(weight loss, polyuria, polydipsia), or history of diabetic ketoaci-
dosis or ketonemia and need to use insulin without interruption
since the diagnosis; age≥13 years and diabetes duration≥5 years.
Exclusion criteria were pregnancy, lactation, chronic alcoholism,
congestive heart failure, cardiac arrhythmias, acute respiratory
failure or severe obstructive lung disease, infections, and acute
complications of diabetes.
The following clinical and demographic data were obtained
through an interview during a clinical visit: sex, age (years), weight
(kg), height (m), body mass index [BMI (Kg/m2)], systolic (sBP)
and diastolic blood pressure [dBP (mmHg)], HR, ethnicity, age
at diagnosis (years), duration of diabetes (years), smoking status,
alcohol consumption, daily insulin dose, use of other medications,
and associated diseases.
Body mass index was calculated by dividing weight (kg) by
height squared (m2). Individuals aged ≥18 years and BMI ≥25
and 30 kg/m2, were considered as overweight and obesity respec-
tively and in subjects <18 years overweight was defined if BMI
≥85th percentile and obesity if BMI ≥95th percentile, accord-
ing with growth charts from Center for Disease Control CDC),
respectively (25).
Hypertension was defined as sBP ≥140 mmHg and/or dBP
≥90 mmHg or on therapy for hypertension (26) and in subjects
<18 years as sBP and/or dBP>95 percentile according to sex, age,
and height (27).
The following laboratory variables were performed: fasting
plasma glucose (FPG), postprandial glucose (PPG), glycated
hemoglonin (HbA1c), total cholesterol, high density lipoprotein
(HDL), triglycerides, uric acid, plasma creatinine, plasma urea,
sodium, potassium, liver enzymes [aspartate (AST) and alanine
aminotransferase (ALT)], creatine phosphokinase (CPK), thyroid
stimulating hormone (TSH), free T4, cyanoconalamin, and C-
reactive protein (CRP). The low-density lipoprotein (LDL) was
calculated using the Friedewald formula (LDL= total choles-
terol−HDL+Triglycerides/5), when the values of triglycerides
did not exceed 400 mg/dl (28).
Screening for retinopathy by fundoscopy and nephropathy
by albuminuria and determination of glomerular filtration rate
(GFR) was performed.
The diagnosis of micro and macroalbuminuria was established
by urinary albumin concentration of respectively 17–173 mg/dl
and ≥174 mg/dl, at least two random urine specimen (29). The
GFR was calculated from the chronic kidney disease epidemi-
ology collaboration (CKD-EPI) (30) equation in patients aged
>16 years and the Schwartz equation for children and adoles-
cents and was considered normal if GFR >60 ml/min/1.73 m2
(31, 32).
Screening for sensory motor neuropathy was performed by the
neuropathic disability score (NDS) and neuropathic impairment
score (NIS) (33, 34).
The evaluation of CAN was performed according to the proto-
col described elsewhere (19). Briefly, the subjects were instructed
to refrain from drinking alcohol- or caffeine-containing beverages
and to engage in smoking cessation for a minimum of 8 h prior
to testing and to refrain from strenuous exercise for at least 24 h
preceding the examination. The exclusion criteria were fever in the
last two days, emotional distress on the day before the autonomic
tests and arrhythmias.
Autonomic tests were performed in the morning. Subjects were
instructed to assume the supine position in a metabolic unit with
a controlled temperature (23°C) after an overnight fast or at least
2 h after a light meal (containing a total of 300 Kcal) standardized
by a dietitian.
After 5 min of rest in the supine position with the head elevated
30° and after 5 min of breathing spontaneously, an electrocardio-
gram (EKG) was recorded for 300 s using a computer. The EKG
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was analyzed by a mathematical algorithm (fast Fourier trans-
form) and expressed in a diagram of oscillation amplitude (HR
variations per second) versus frequency (Hz).
The autonomic tests are described below. After each test, a rest-
ing period of 1 min was scheduled to prevent influences by the
previous tests.
DEEP BREATHING TEST
The subject was kept in the supine position for at least 1 min and
then invited to start the test with a deep inspiration to the max-
imum total lung capacity for 5 s, which was followed by a forced
expiration down to the residual volume for 5 s. The time to alter-
nate the respiratory cycle is signaled directly to the patient by the
operator. Such a respiratory cycle was repeated three times. The
expiration:inspiration ratio (E:I ratio) was determined by the ratio
between the longest and shortest RR intervals obtained during the
expiration and inspiration cycles, respectively, and the highest E:I
ratio was considered (16).
VALSALVA MANEUVER
Without taking a deep breath beforehand, the subject, who was
in the supine position, was invited to blow with an open glottis
into a mouthpiece connected to a manometer and to maintain a
constant expiratory effort equivalent to an intraoral pressure of
40 mmHg for 15 s. This test induces a physiological tachycardia,
which persists for a maximum of approximately 14 s. After this
period, the expiratory straining is suddenly released, and the sub-
ject should breathe regularly and remain silent and motionless
until the end of the test. An EKG was continuously recorded for
70 s, when the physiological bradycardia is observed. The Valsalva
ratio was determined by the ratio between the longest and shortest
RR intervals. The occurrence of facial flushing, plethora, and neck
vein engorgement testify to the correctness of the maneuver (7,
24). The test was performed twice, and the highest Valsalva ratio
was considered.
ORTHOSTATIC TEST
After lying in the supine position for at least 5 min, the subject
was invited to stand up quickly but remain relaxed with their arms
at rest alongside the body and without speaking or moving until
the end of the test (180 s after standing up). The 30:15 or max-
imum:minimum (max:min) ratio was determined by the ratio
between the longest (maximum bradycardia at approximately the
30th beat) and shortest (maximum tachycardia at approximately
the 15th beat) RR intervals.
ORTHOSTATIC HYPOTENSION TEST
After at least 5 min of supine rest, the blood pressure was measured
at baseline and after 3 min of standing. A drop in the systolic blood
pressure that was higher than or equal to 20 mmHg was considered
abnormal (7, 24).
The diagnosis of incipient and defined CAN was considered in
the presence of one and two abnormal cardiovascular reflex tests,
respectively (17, 35).
Statistical analysis
The statistical analysis was performed using Statistical Package
for Social Sciences (SPSS) for Windows (version 13.0). The data
Table 1 | Clinical and demographic data of the studied population.
Variable
N 151
Age (years) 33.4±13
Gender, female (%) 81 (53.6)
Ethnicity, Caucasian (%) 69 (45.7)
Age at diagnosis (years) 17.2±9.8
Diabetes duration (years) 16.3±9.5
BMI (Kg/m2) 23.4 (13.7–37.9)
Abdominal circumference (cm) 79.8±9.8
Hypertension, n (%) 36 (23.8)
Current smoker, n (%) 11 (7.3)
sBP (mmHg) 124.6±16.6
dBP (mmHg) 75.1±10.4
Heart rate (bpm) 79 (50–134)
HbA1c (%) 9.1±2
Fasting glycemia (mg/dl) 170 (21–561)
Postprandial glycemia 223±95
Total cholesterol (mg/dl) 176 (98–330)
Triglycerides (mg/dl) 79 (32–748)
HDL-c (mg/dl) 62.9 (32.7–165.8)
LDL-c (mg/dl) 94±27.4
Lipid-lowering mediations, n (%) 49 (32.5)
BP-lowering medications, n (%) 55 (33.8)
Diabetic retinopathy, n (%) 55 (37.7)
Normoalbuminuria/microalbuminuria)
macroalbuminuria, n (%)
110 (75.9)/32 (23.4)/1 (0.7)
Diabetic neuropathy, n (%) 44 (29.1)
The data are presented as counts (percentage), means±SD, or medians (mini-
mum/maximum).
BMI, body mass index; sBP, systolic blood pressure; dBP, diastolic blood pressure;
BP, blood pressure; GFR, glomerular filtration rate.
are presented as mean± SD and median (minimum–maximum).
Comparison between numeric variables was performed using t -
test and Mann–Whitney test for variables with normal or skewed
distribution, respectively. The chi-square test was used to compare
the frequencies of two categorical variables. A Pearson’s correla-
tion coefficient was calculates when applicable. Adjustments were
made for potential confounders. A binary logistic regression was
performed with diagnosis of CAN (yes/no) as the dependent vari-
able. The following independent variables were included: sex, age,
diabetes duration, pulse pressure, resting HR, BMI, hypertension,
presence of micro or macroalbuminuria, presence of diabetic neu-
ropathy and retinopathy, HbA1c, urea, creatinine, LDL cholesterol,
and hemoglobin. Odds ratios with 95% confidence intervals (CI)
were performed when indicated. A two-sided p-value less than
0.05 was considered significant.
RESULTS
One hundred and fifty-one patients with T1D were evaluated.
Clinical and demographic data for the study population are
presented in Table 1.
Table 2 presents the variables used for assessment of CAN
in the study population and in subgroups of patients with
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Table 2 | Variables used for assessment of CAN.
Frequency domain variables All patients Presence of CAN Absence of CAN p
VLF (ms2) 395 (11.4–8159) 154.5 (11.4–1308) 676 (48.9–8159) 0.000
LF (ms2) 301 (2.1–4568) 50.5 (2.1–2899) 565 (37.6–4568) 0.000
HF (ms2) 244 (3.9–8381) 43 (3.9–6590) 463 (16.3–8381) 0.000
VLF (%) 38.4±18.9 51 (12.1–89.5) 33.6 (7.9–84.5) 0.000
LF (%) 27.4±11.9 24±11.7 28.9±11.8 0.019
HF (%) 29 (4.1–74.2) 19.8 (4.1–63.9) 30.2 (3.7–76.5) 0.003
LF/HF ratio 0.97 (0.1–27.9) 1.1 (0.1–8.4) 1 (0.1–27.9) 0.509
TIME DOMAIN VARIABLES
RR min (ms) 676 (30–1127) 663.5 (502–1127) 688 (30–1052) 0.297
RR max (ms) 903 (597–12266) 760.5 (597–2854) 943 (734–12266) 0.000
RRNN (ms) 799 547–1378) 707 (547–1195) 817 (618–1378) 0.000
SDNN (ms) 32 (4–155) 14 (4–155) 40 (13–147) 0.000
RMSSD (ms) 23 (1–157) 8.5 (1–157) 30 (7–140) 0.000
CV (%) 4 (0.7–21.9) 2 (0.7–21.9) 5.1 (1.6–15.5) 0.000
TP (ms) 1185 (26–15880) 377.5 (26–10797) 2125 (192–15880) 0.000
pNN50 1.59 (0–77.1) 0 (0–13.2) 7.7 (0–77.1) 0.000
CARDIOVASCULAR REFLEXTESTS (GOLD STANDARD)
Max–min ratio 1.36 (1.01–2.2) 1.15 (1.01–1.9) 1.44 (1.09–2.2) 0.000
Valsalva ratio 1.71 (1.04–3.74) 1.37 (1.04–2.54) 1.9 (1.39–3.74) 0.000
E:I ratio 1.36 (0.98–2.28) 1.1 (0.98–1.75) 1.45 (1.12–2.28) 0.000
Decrease in sBP (mmHg) 3 (−27–35) 7.5 (−27–35) 2 (−20–17) 0.000
Decrease in sBP ≥20 mmHg,
yes, n (%)
10 (6.6) 10 (6.6) 0 0.000
RR min, RR minimum; RR max, RR maximum; RRNN, mean RR intervals; SDNN, standard deviation of all normal to normal RR intervals; CV, coefficient of variation;
RMSDD, the root mean squared successive difference between adjacent RR intervals; TP, total power; pNN50, percentage of intervals between consecutive normal
beats that exceed 50 ms;VLF, very low frequency; LF, low frequency; HF, high frequency; E:I ratio, expiration to inspiration ratio;Valsalva ratio, Max: min ratio, maximum
to minimum ratio; sBP, systolic blood pressure.
The data are presented as counts (percentage), means±SD, or medians (minimum/maximum).
and without CAN. The prevalence of CAN as assessed only
by HRV (spectral analysis) was higher than the prevalence of
CAN assessed by cardiovascular reflex tests and showed moder-
ate agreement (kappa= 0.44/p= 0.074). Data about the preva-
lence of CAN according to the diagnostic criteria are shown in
Table 3.
The prevalence of autonomic symptoms in the general popu-
lation, in patients with and without CAN is shown in Table 4.
Symptoms associated with the presence of CAN were syn-
cope (p= 0.000), postprandial nausea (p= 0.042), early sati-
ety (p= 0.031), sexual dysfunction (p= 0.049), and gustatory
sweating (p= 0.018).
The clinical and laboratory predictors of CAN found in
the studied population were age (p= 0.01), diabetes duration
(p= 0.036), hypertension (p= 0.048), resting HR (p= 0.000),
HbA1c (p= 0.048), urea (p= 0.000), creatinine (p= 0.008),
GFR (p= 0.000), urinary albumin concentration (p= 0.000),
LDL-cholesterol (p= 0.048), free T4 (p= 0.023), and hemo-
globin (p= 0.01) (Table 5). All microvascular chronic com-
plications were related to the presence of CAN (Table 5).
Only 1 (2.2%) patients with CAN presented levels of HbA1c
lower than 7% compared with 18 (17.2%) in patients without
CAN (p= 0.011).
Table 3 | Prevalence of CAN according to the diagnostic criteria.
CAN prevalence
Total NAC
defined
NAC
incipient
Cardiovascular reflex tests+HRV
(spectral analysis), n (%)
53 (35.1) 39 (25.8) 14 (9.3)
Cardiovascular reflex tests, n (%) 46 (30.5) 17 (11.3) 29 (19.2)
HRV (spectral analysis), n (%) 61 (40.4) 51 (33.8) 10 (6.6)
HRV, heart rate variability; CAN, cardiovascular autonomic neuropathy.
After logistic regression model using diagnosis of CAN by
cardiovascular reflex testes as a dependent variable and sex,
age, diabetes duration, pulse pressure (calculated as the dif-
ference between the sBP and dBP), resting HR, BMI, hyper-
tension, albuminuria, presence of diabetic neuropathy and
retinopathy, HbA1c, urea, creatinine, LDL, and hemoglobin as
independent variables, it was observed that only resting HR,
presence of diabetic neuropathy and retinopathy were signifi-
cantly independent variables associated with the diagnosis of
CAN (Table 6).
Frontiers in Endocrinology | Diabetes November 2014 | Volume 5 | Article 191 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tannus et al. Predictors of cardiovascular autonomic neuropathy
Table 4 | Prevalence of autonomic symptoms in patients with and without CAN.
Autonomic symptoms Patients p
Total Presence of CAN Absence of CAN
Syncope, n (%) 25 (16.6) 15(32.6) 10(9.5) 0.000
Postprandial nausea, n (%) 20 (13.2) 10 (21.7) 10 (9.5) 0.042
Early satiety, n (%) 30 (19.9) 14 (30.4) 16 (15.2) 0.031
Diarrhea, n (%) 5 (3.3) 4 (8.7) 1 (1) 0.051
Constipation, n (%) 43 (28.5) 17 (37) 26 (24.8) 0.126
Recurrent urinary infection, n (%) 9 (6) 5 (10.9) 4 (3.8) 0.189
Pollakiuria, n (%) 6 (4) 3 (6.5) 3 (2.9) 0.543
Sexual dysfunction, n (%) 34 (22.5) 15 (32.6) 19 (18.1) 0.049
Gustatory sweating, n (%) 16 (10.6) 9 (19.6) 7 (6.7) 0.018
Asymptomatic hypoglycemia, n (%) 55(44.7) 15 (39.5) 40 (47) 0.434
CAN, cardiovascular autonomic neuropathy.
DISCUSSION
In the present study, the prevalence of incipient, defined, and
total CAN in patients with T1D and T1D duration ≥5 years was
19.2, 11.3, and 30.5%, respectively when used only cardiovascular
reflex tests; 6.6, 33.8, and 40.4% when using the HRV parame-
ters (spectral analysis) and 9.3, 25.8, and 35.1% when used both
criteria. The prevalence of CAN assessed by cardiovascular reflex
tests was lower than the prevalence reported in the literature (11.3
versus 25%), but quite similar when using cardiovascular reflex
tests associated with the HRV parameters (spectral analysis) (25.8
versus 25%). As we can see, the prevalence of CAN defined by
HRV (spectral analysis) was superior to cardiovascular reflex tests,
which could corroborate the data from the literature regarding the
sensitivity and early detection of cardiovascular autonomic dys-
function by this diagnostic criterion. However, the diagnosis of
CAN based only on spectral analysis must be carefully considered
since previous study from our group (19) demonstrated that the
assessment of HRV by spectral analysis (VLF, LF and HF) showed
low reproducibility.
The agreement of CAN diagnosis for the two diagnostic meth-
ods (cardiovascular reflex tests versus spectral analysis) was mod-
erate. Therefore, analysis of CAN using only frequency-domain
HRV analysis should be considered an additional tool for CAN
diagnosis according to other studies (16–18, 36).
The incidence of CAN increases with age, diabetes duration
and poor glycemic control. (7,8) In this study, clinical and labora-
tory predictors of CAN were age, T1D duration>10 and 20 years,
hypertension, resting HR, HbA1c, LDL-c, urea, creatinine, free T4
and hemoglobin, and the presence of retinopathy, nephropathy
and diabetic peripheral neuropathy. Slightly higher levels of free
T4, even within the normal range were found in patients with T1D
and CAN, possibly suggesting a sympathovagal imbalance (16).
Some studies showed that CAN can reduce the renal release of
erythropoietin probably by renal denervation, leading to the devel-
opment of anemia (37, 38). In our study, we observed that patients
with T1D and CAN had lower hemoglobin levels, corroborating
the above mentioned data. Patients with T1D and proteinuria may
have anemia by erythropoietin deficiency, even in the absence of
changes in GFR (38).
However, it is difficult to differentiate whether the anemia was
a result of CAN or diabetic nephropathy since these two diabetic
complications are frequently associated.
Several studies have suggested a causal relationship between
CAN and diabetic nephropathy (39, 40). Forsen et al (39) evalu-
ated the prevalence of microalbuminuria and CAN after 14 years
of follow-up and observed that CAN precedes the development of
albuminuria in patients with T1D. In patients with T1D and CAN,
the sympathovagal imbalance (assessed by abnormal E:I ratio)
promotes increase in nocturnal BP (reduction of parasympathetic
activity) with consequent overnight increase in intraglomerular
pressure, and daytime reduction in intraglomerular pressure as a
result of postural hypotension (39, 41). CAN appears to be a per-
missive factor for the development of persistent microalbuminuria
(39). In our study urinary albumin concentration and GFR were
associated with the presence of CAN,corroborating the association
of these two complications. This study was a cross-sectional study
and could not establish a causal relationship between diabetic
nephropathy and CAN.
Inflammatory markers such as CRP and IL-6 have been corre-
lated with abnormal HRV (6). One study evaluated 611 healthy
subjects and showed an inverse correlation between CRP levels
and HRV parameters (42). Ridker et al (43, 44) have shown an
association of CRP levels >3 mg/dl with high cardiovascular risk.
In the current study, we found no statistically significant associa-
tion between CRP levels and CAN, which could be explained by
the fact that only 8 patients had CRP levels ≥3 mg/dl.
Autonomic symptoms, although disabling, appears in more
advanced stages of CAN, have low sensitivity and specificity and
have low association with abnormal cardiovascular reflex tests (6,
17, 18). Symptoms associated with CAN in this study symptoms
were syncope, postprandial nausea, early satiety, sexual dysfunc-
tion and gustatory sweating. Therefore, autonomic symptoms did
not seems to represent sensitive indicators for early diagnosis of
CAN (16).
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Table 5 | Predictors of CAN in the studied population.
Presence of CAN Absence of CAN p
Female/male (%) 65.2/34.8 48.6/51.4 0.059
Caucasian/not Caucasian (%) 39.1/60.9 56.2/47.6 0.284
Age (years) 37.5±12.7 31.6±12.8 0.010
Age at diagnosis (years) 19.9±9 16.4±10.1 0.137
T1D duration (years) 18.5±8.7 15.3±9.8 0.051
T1D duration (<5/5–10/10–20/>20 years) (%) 4.4/15.2/39.1/41.3 11.4/23.8/44.7/37.6 0.036
Smokers, yes (%) 10.9 5.7 0.434
Alcohol consumption, yes (%) 19.6 16.2 0.631
BMI (Kg/m2) 22.7 (16.7–37.9) 23.6 (13.7–33.6) 0.505
Overweight/obesity, yes (%) 30.4 37.1 0.464
sBP (mmHg) 127.6±19.7 123.3±14.9 0.145
dBP (mmHg) 76.3±10.4 74.5±10.5 0.345
Hypertension, yes (%) 41.3 16.2 0.001
Resting heart rate (bpm) 87.3±15.6 76.1±11.1 0.000
Abdominal circumference (cm) 78±9.6 80.6±9.8 0.140
Fasting glycemia (mg/dl) 154 (44–364) 132 (24–548) 0.418
Postprandial glycemia (mg/dl) 240.2±103.6 204.8±96.5 0.056
HbA1c (%) 9.8±2.4 8.9±2.2 0.048
HbA1c <7%, n (%) 1 (2.2) 18 (17.1) 0.011
Urea (mg/dl) 34 (4–85) 27 (14–60) 0.000
Creatinine (mg/dl) 1.1 (0.52–2.68) 0.96 (0.44–1.45) 0.008
Uric acid (mg/dl) 4.8±1.3 4.3±1.2 0.055
Total cholesterol (mg/dl) 190 (117–330) 171 (110–193) 0.051
Triglycerides (mg/dl) 79 (37–320) 79 (32–507) 0.539
HDL-c (mg/dl) 65 (39.4–165.8) 62.9 (32.7–112.2) 0.563
LDL-c (mg/dl) 99.1±25.2 89.7±26.6 0.048
Dyslipidemia, yes (%) 45.7 29.5 0.055
CRP (mg/dl) 0.2 (0.01–4.33) 0.13 (0.01–3.4) 0.523
CRP (<1/1–3/>3 mg/dl), (%) 77.3/18.2/4.5 85.1/8.9/5.9 0.275
TSH (µUI/ml) 2.34 (1.35–6.93) 1.66 (0.32–5.61) 0.134
Free T4 (µUI/ml) 1.3±0.3 1.2±0.2 0.023
Hemoglobin (g/dl) 12.7±1.6 13.4±1.5 0.010
Urinary albumin concentration (mg/dl) 15.5 (1.77–152.3) 8.1 (0.1–257.3) 0.000
GFR (ml/min/1.73 m2) 86.8±38.6 109.9±35.8 0.000
Abnormal GFR (<60 ml/min/1.73 m2) (%) 19.6 5.7 0.009
Retinopathy, yes (%) 76.7 29.4 0.000
Nephropathy, yes (%) 47.7 13.9 0.000
Neuropathy, yes (%) 58.7 16.2 0.000
Coronary artery disease, yes (%) 6.5 3.8 0.757
Hypothyroidism, yes (%) 8.7 9.5 0.872
T1D, type 1 diabetes mellitus; BMI, body mass index; sBP, systolic blood pressure; dBP, diastolic blood pressure; HbA1c, glycated hemoglobin; HDL-c, high density
lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; CRP, C-reactive protein; TSH, thyroid stimulating hormone.
Values are presented as mean±SD and median (minimum–maximum).
This study is one of the first studies that evaluated the preva-
lence of CAN assessed by the gold standard cardiovascular reflex
tests as recommended by the ADA in the Brazilian population, thus
allowing the identification of patients with T1D and increased car-
diovascular risk. Moreover, this study allowed the identification of
some clinical factors that might suggest the diagnosis of CAN.
The study had some limitations. Because this was a cross-
sectional study we could not establish a causal relationship
between the predictors and the diagnosis of CAN. Another lim-
itation is related to data collection on hypoglycemia. Patients
self-reported the number and severity of hypoglycemic episodes in
the last month. It was not possible to obtain data through the glu-
cometer of all patients, which could underestimate the prevalence
of hypoglycemia.
In conclusion, CAN is a common chronic complication of T1D
affecting about 30% of the studied population and is associated
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Table 6 | Logistic regression with the diagnosis of cardiovascular
reflex tests as the dependent variable.
B p* OR IC (95%)
Resting heart rate 0.124 0.001 1.13 1.06–1.22
Diabetic neuropathy 1.913 0.011 6.77 1.56–29.4
Diabetic retinopathy 1.939 0.008 6.95 1.68–28.8
*p<0.05; OR, odds ratio; CI, confidence interval of 95%; dBP, diastolic blood
pressure.
with the presence of other chronic complications of T1D. Indica-
tors of the presence of CAN included age, duration of diabetes,
presence of hypertension, resting HR, presence of diabetic neu-
ropathy and retinopathy and symptoms suggestive of autonomic
neuropathy. This study confirms the importance of systematic and
early screening for this complication.
AUTHOR CONTRIBUTIONS
Lucianne Righeti Monteiro Tannus and Marilia Brito Gomes
researched data, drafted the manuscript. Karla Rezende Guerra
Drummond, Eliete Leão da Silva Clemente, and Maria de Fátima
Bevilacqua da Matta contributed to the conception of the work
and the acquisition of data for the work. Lucianne Righeti Mon-
teiro Tannus and Marilia Brito Gomes reviewed the manuscript
and contributed to the discussion. The writing group takes final
responsibility for the paper and is the study guarantor.
ACKNOWLEDGMENTS
We thank Elisangela Santos for her technical assistance. This
work was supported by grants from Farmanguinhos/Fundação
do Amparo à Pesquisa do Estado do Rio de Janeiro, and Conselho
Nacional de Desenvolvimento Científico e Tecnológico do Brasil
(5637532010/2).
REFERENCES
1. American Diabetes Association. Diabetes statistics for Youth. American Dia-
betes Association (2004). http://www.niddk.nih.gov/news/research-updates/
Pages/Rates-of-Diabetes-Increasing-in-U-S--Youth.aspx
2. DCCT Research Group. The effect of intensive treatment of diabetes on the
development and progression of long-term complications in insulin depen-
dent diabetes mellitus. The Diabetes Control and Complications Trial Research
Group. NEJM (1993) 329:977–86. doi:10.1056/NEJM199309303291401
3. Libby P, Nathan DM, Abraham K, Brunzell JD, Fradkin JE, Haffner SM, et al.
Report of the National Heart, Lung, and Blood Institute; National Institute of
Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascu-
lar Complications of Type 1 Diabetes Mellitus. Circulation (2005) 111:3489–93.
doi:10.1161/CIRCULATIONAHA.104.529651
4. Zgibor CJ, Piatt GA, Ruppert K, Orchard TJ, Roberts MS. Deficiencies of car-
diovascular risk prediction models for type 1 diabetes. Diabetes Care (2006)
8:1860–5. doi:10.2337/dc06-0290
5. Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waugh NR, et al. Mor-
tality from heart disease in a cohort of 23,000 patients with insulin-treated
diabetes. Diabetologia (2003) 46:760–5. doi:10.1007/s00125-003-1116-6
6. Vinik AI, Erbas T, Casellini CM. Diabetic cardiac autonomic neuropathy,
inflammations and cardiovascular disease. J Diabetes Investigat (2013) 4:4–18.
doi:10.1111/jdi.12042
7. Rolim LCS, Sá JR, Chacra AR, Dib AS. Diabetic cardiovascular autonomic neu-
ropathy: risk factors, clinical impact and early diagnosis.Arq Bras Cardiol (2008)
90:e23–31. doi:10.1590/S0066-782X2008000400014
8. Schmid H. Impacto cardiovascular da neuropatia autonômica do diabetes
mellitus. Arq Bras Endocrinol Metabol (2007) 51:232–43. doi:10.1590/S0004-
27302007000200012
9. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation
(2007) 115:387397. doi:10.1161/CIRCULATIONAHA.106.634949
10. Prince CT, Secrest AM, Mackey RH, Arena VC, Kingsley LA, Orchard TJ. Cardio-
vascular autonomic neuropathy, HDL cholesterol, and smoking correlate with
arterial stiffness markers determined 18 years later in type 1 diabetes. Diabetes
Care (2010) 33:652–7. doi:10.2337/dc09-1936
11. Frans JTH, Wackers FJT, Young LH, Inzucchi SE, Chyun DA, Davey JA, et al.
For the detection of ischemia in asymptomatic diabetics (DIAD) investigators.
Detection of silent myocardial ischemia in asymptomatic diabetic subjects. Dia-
betes Care (2004) 27:1954–61. doi:10.2337/diacare.27.8.1954
12. Wackers FJT, Chyun DA, Young LH, Heller GV, Iskandrian AE, Davey JA, et al.
For the detection of ischemia in asymptomatic diabetics (DIAD) investigators.
Resolution of asymptomatic myocardial ischemia in patients with type 2 dia-
betes in the detection of ischemia in asymptomatic diabetics (DIAD) study.
Diabetes Care (2007) 30:2892–8. doi:10.2337/dc07-1250
13. Wackers FJT, Chyun DA, Young LH, Heller GV, Iskandrian AE, Davey JA, et al.
For the detection of ischemia in asymptomatic diabetics (DIAD) investigators.
Cardiac outcomes after screening for asymptomatic coronary artery disease
in patients with type 2 diabetes. JAMA (2009) 15:1547–55. doi:10.1001/jama.
2009.476
14. Pop-Busui R, Evans G, Gerstein H, Fonseca V, Fleq JL, Hooqwerf BJ, et al. The
ACCORD study group. Effects of cardiac autonomic dysfunction on mortality
risk in the action to control cardiovascular risk in diabetes (ACCORD) Trial.
Diabetes Care (2010) 33:1578–84. doi:10.2337/dc10-0125
15. American Diabetes Association and American Academy of Neurology: Consen-
sus Statement. Report and recommendations of the San Antonio conference on
diabetic neuropathy. Diabetes Care (1988) 11:592–7.
16. Spallone V, Bellavere F, Scionti L, Maule S, Quadril R, Bax G, et al. On behalf
of the Diabetic Neuropathy Study Group of the Italian Society of Diabetol-
ogy. Recommendations for the use of cardiovascular tests in diagnosing dia-
betic autonomic neuropathy. Nutrit Metab Cardiovasc Dis (2011) 21:69–78.
doi:10.1016/j.numecd.2010.07.005
17. Tesfaye S, Boulton AJM, Dyck PJ, Freman R, Horowitz M, Kempler P, et al.
Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of
severity, and treatments. On behalf of the Toronto Diabetic Neuropathy Expert
Group. Diabetes Care (2010) 33:2285–93. doi:10.2337/dc10-1303
18. Spallone V, Ziegler D, Freeman R, Bernardi L, Frontoni S, Pop-Busui R, et al. On
behalf of the Toronto Consensus Panel on Diabetic Neuropathy. Cardiovascular
autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and
management.DiabetesMetab Res Rev (2011) 27:639–53. doi:10.1002/dmrr.1239
19. Tannus LRM, Sperandei S, Junior RMM, Carvalho VR, Pedrosa HC, Félix
MT, et al. Reproducibility of methods used for the assessment of autonomous
nervous system´s function. Autonom Neurosci Basic Clin (2013) 177:275–9.
doi:10.1016/j.autneu.2013.05.444
20. O’Brien IAD, O’Hare P, Corrall RJM. Heart rate variability in healthy subjects:
effect of age and the derivation of normal ranges for testes of autonomic func-
tion. Br Heart J (1986) 55:348–54. doi:10.1136/hrt.55.4.348
21. Kowalewski MA, Urban M. Short and long term reproducibility of auto-
nomic measures in supine and standing positions. Clin Sci (2004) 106:61–6.
doi:10.1042/CS20030119
22. Lobnig BM, Maslowska-Wessel E, Bender R. Repeatability of heart rate variabil-
ity measured via spectral analysis in healthy subjects. J Clin Basic Cardiol (2003)
6:29–33.
23. Gerritsen J, TenVoorde BJ, Dekker JM, Kingma R, Kostense PJ, Bouter LM, et al.
Measures of cardiovascular autonomic nervous function: agreement, repro-
ducibility, and reference values in the middle age and elderly subjects.Diabetolo-
gia (2003) 46:330–8. doi:10.1007/s00125-003-1032-9
24. Ziegler D, Laux G, Dannehi K, Spuler M, Mayer P, Gries FA. Assessment of
Cardiovascular Autonomic Function: age related normal ranges and repro-
ducibility of spectral analysis, vector analysis and standard tests of heart
rate variation and blood pressure responses. Diabet Med (1992) 9:166–75.
doi:10.1111/j.1464-5491.1992.tb01754.x
25. de Onis M, Habicht JP. Anthropometric reference data for international use:
recommendations from a World Health Organization Expert Committee. Am J
Clin Nutr (1996) 64(4):650–8.
www.frontiersin.org November 2014 | Volume 5 | Article 191 | 7
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tannus et al. Predictors of cardiovascular autonomic neuropathy
26. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al.
Seventh report of the joint national committee on prevention, detection, evalua-
tion, and treatment of high blood pressure. Hypertension (2003) 42(6):1206–52.
doi:10.1161/01.HYP.0000107251.49515.c2
27. National High Blood Pressure Education Program Working Group on High
Blood Pressure in Children and Adolescents. The fourth report on the diagnosis,
evaluation, and treatment of high blood pressure in children and adolescents.
Pediatrics (2004) 114(Suppl 2):555–76.
28. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of
low-density lipoprotein cholesterol in plasma, without use of the preparative
ultracentrifuge. Clin Chem (1972) 14:492–9.
29. Leitão CB, Canani LH, Bolson PB, Molon MP, Silveiro SP, Gross JL. Que val-
ores devem ser adotados para o diagnóstico de microalbuminúria no Dia-
bete Melito? Arq Bras Endocrinol Metab (2006) 50:322–6. doi:10.1590/S0004-
27302006000200018
30. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate
accurate method to estimate glomerular filtration rate from serum creatinine:
a new prediction equation. Modification of Diet in Renal Disease Study Group.
Ann Intern Med (1999) 130(6):461–70.
31. Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, et al.
New equations to estimate GFR in children with CKD. J Am Soc Nephrol (2009)
20(3):629–37. doi:10.1681/ASN.2008030287
32. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group.
Clinical practice guideline for the evaluation and management of chronic kidney
disease. Kidney Int Suppl (2013) 3:1–150.
33. Moreira RO, Castro AP, Papelbaum M, Appolinário JC, Ellinger VC, Coutinho
WF, et al. Tradução para o Português e Avaliação da Confiabilidade de Uma
Escala para Diagnóstico da Polineuropatia Distal Diabética. Arq Bras Endocrinol
Metab (2005) 49:944–50. doi:10.1590/S0004-27302005000600014
34. Young MJ, Boulton AJM, Macleod AF, Williams DRR, Sonksen PH. A mul-
ticentre study of the prevalence of diabetic peripheral neuropathy in the
United Kingdom hospital clinic population. Diabetologia (1993) 36:150–4.
doi:10.1007/BF00400697
35. Boulton AJM, Vinik AI, Arezzo JC, Bril V, Feldman EL, Malik RA, et al. Diabetic
neuropathies. A statement by the American Diabetes Association. Diabetes Care
(2005) 28:956–62. doi:10.2337/diacare.28.4.956
36. Rolim LC, Souza JST, Dib SA. Tests for early diagnosis of cardiovascular auto-
nomic neuropathy: critical analysis and relevance. Front Endocrinol (2013)
4:173. doi:10.3389/fendo.2013.00173
37. Thomas MC, MacIsaac RJ, Tsalamandris C, Molyneaux L, Goubina I, Fulcher G,
et al. Anemia in Patients with Type 1 Diabetes. J Clin Endocrinol Metab (2004)
89:4359–63. doi:10.1210/jc.2004-0678
38. Bosman DR, Osborne CA, Marsden JT, Macdougall IC, Gardner WN, Watkins
PJ. Erythropoietin response to hypoxia in patients with diabetic autonomic
neuropathy and non-diabetic chronic renal failure. Diabet Med (2002) 19:65–9.
doi:10.1046/j.1464-5491.2002.00634.x
39. Forsén A, Kangro M, Sterner G, Norrgren K, Thorsson O, Wollmer P, et al.
A 14-year prospective study of autonomic nerve function in Type 1 dia-
betic patients: association with nephropathy. Diabet Med (2004) 21:852–8.
doi:10.1111/j.1464-5491.2004.01255.x
40. Sundkvist G, Ljlia B. Autonomic neuropathy predicts deterioration in glomeru-
lar filtration rate in patients with IDDM. Diabetes Care (1993) 16:773–9.
doi:10.2337/diacare.16.5.773
41. Lafferty AR,Werther GA, Clarke CF. Ambulatory blood pressure, microalbumin-
uria, and autonomic neuropathy in adolescents with type 1 diabetes. Diabetes
Care (2000) 23:533–8. doi:10.2337/diacare.23.4.533
42. Thayer JF, Fischer JE. Heart rate variability, overnight urinary norepinephrine
and C-reactive protein: evidence for the cholinergic anti-inflammatory pathway
in healthy human adults. J Intern Med (2009) 265:439–47. doi:10.1111/j.1365-
2796.2008.02023.x
43. Blake GJ, Rifai N, Buring JE, Ridker PM. Blood pressure, C-reactive pro-
tein, and risk of future cardiovascular events. Circulation (2003) 108:2993–9.
doi:10.1161/01.CIR.0000104566.10178.AF
44. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease
detection and prevention. Circulation (2003) 107:363–9. doi:10.1161/01.CIR.
0000053730.47739.3C
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 29 July 2014; accepted: 18 October 2014; published online: 25 November
2014.
Citation:Tannus LRM,Drummond KRG,Clemente ELdS, daMattaMdFBandGomes
MB (2014) Predictors of cardiovascular autonomic neuropathy in patients with type 1
diabetes. Front. Endocrinol. 5:191. doi: 10.3389/fendo.2014.00191
This article was submitted to Diabetes, a section of the journal Frontiers in
Endocrinology.
Copyright © 2014 Tannus, Drummond, Clemente, da Matta and Gomes. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original publica-
tion in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Endocrinology | Diabetes November 2014 | Volume 5 | Article 191 | 8
